17 results
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
6 Nov 23
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
9:04am
this tenure, he led multiple
research teams in developing and incorporating predictive biomarker strategies across all phases of clinical trials
DEF 14A
ZNTL
Zentalis Pharmaceuticals Inc
23 Apr 21
Definitive proxy
4:05pm
development start-up to an organization of approximately 200 employees with 20 acalabrutinib clinical studies. His Acerta tenure included … Corporation, a global pharmaceutical company focusing on therapies to treat cancer and inflammatory diseases. During her tenure with Celgene, from
10-K
2020 FY
ZNTL
Zentalis Pharmaceuticals Inc
25 Mar 21
Annual report
7:17am
acalabrutinib from early to late-stage global clinical development. His tenure at Acerta culminated in the execution of a strategic transaction … at Merck & Co., Inc., a multinational pharmaceutical company, from 1997 to 2015. Over her 18-year tenure at Merck, Ms. Pinto held numerous positions
424B4
unsw2ho zn
31 Jul 20
Prospectus supplement with pricing info
12:00am
DRS
EX-10.9
6mbzx539m15 m2e
10 Jul 20
Draft registration statement
12:00am
DRS
EX-10.8
1lt9q aeu
10 Jul 20
Draft registration statement
12:00am
DRS
hl121a2t0hvraix0a
10 Jul 20
Draft registration statement
12:00am
424B4
7cpc3i phaw651kyuj2
6 Apr 20
Prospectus supplement with pricing info
6:13am
S-1
14dw58
6 Mar 20
IPO registration
5:05pm
S-1
EX-10.8
h9yek4
6 Mar 20
IPO registration
5:05pm
S-1
EX-10.9
aztqz7goz6uembzej3he
6 Mar 20
IPO registration
5:05pm
DRS
euxxeitxlxgt
8 Jan 20
Draft registration statement
12:00am
- Prev
- 1
- Next